PRC200-SS is an experimental drug of the triple reuptake inhibitor class that was investigated by the Mayo Clinic.[1][2]

CAS Number
PubChem CID
ECHA InfoCard100.207.294
Chemical and physical data
Molar mass291.394 g·mol−1
3D model (JSmol)
 NY (what is this?)  (verify)

Preclinical toxicology studies of PRC200-SS in cynomolgus monkeys showed dose proportional kidney toxicity,[3] precluding any further drug development.


  1. Liang, Y.; Shaw, A. M.; Boules, M.; Briody, S.; Robinson, J.; Oliveros, A.; Blazar, E.; Williams, K.; Zhang, Y.; Carlier, P. R.; Richelson, E. (2008). "Antidepressant-Like Pharmacological Profile of a Novel Triple Reuptake Inhibitor, (1S,2S)-3-(Methylamino)-2-(naphthalen-2-yl)-1-phenylpropan-1-ol (PRC200-SS)". Journal of Pharmacology and Experimental Therapeutics. 327 (2): 573–583. doi:10.1124/jpet.108.143610.
  2. "Triple Reuptake Inhibitors for the Treatment of Depression". Mayo Clinic Ventures.
  3. Guha, Mausumee; Heier, Annabelle; Price, Sally; Bielenstein, Margareta; Caccese, Robert G.; Heathcote, Daniel I.; Simpson, Thomas R.; Stong, David B.; Bodes, Elmarie (2011). "Assessment of Biomarkers of Drug-Induced Kidney Injury in Cynomolgus Monkeys Treated with a Triple Reuptake Inhibitor". Toxicological Sciences. 120 (2): 269–283. doi:10.1093/toxsci/kfr013.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.